A new novolimus-eluting bioresorbable coronary scaffold: Present status and future clinical perspectives. (15th January 2017)

• Record Type: Journal Article
• Authors: Nef, Holger M.; Wiebe, Jens; Foin, Nicolas; Blachutzik, Florian; Dörr, Oliver; Toyloy, Sara; Hamm, Christian W.
• Is Part Of: International journal of cardiology. Volume 227(2017)
• Page Start: 127
• Page End: 133
• Publication Date: 2017-01-15
• Subjects: Percutaneous coronary intervention -- Novolimus-eluting bioresorbable vascular scaffold -- Coronary artery disease; Cardiology -- Periodicals; Electronic journals; 616.12
• DOI: 10.1016/j.ijcard.2016.11.033
• Languages: English
• ISSNs: 0167-5273

Abstract

Abstract: The DESolve® scaffold (Elixir Medical Corporation, Sunnyvale, California, USA) is manufactured from a poly-l -lactide based polymer and elutes an anti-proliferative, anti-inflammatory drug, Novolimus from a poly-l -lactide based topcoat mixture. The strut thickness is 150 μm and the scaffold has platinum–iridium radiopaque markers at both ends. Radial support is available during the early time period to prevent recoil. The scaffold biodegrades within 1 year (> 90% reduction in molecular weight) and then completely bioresorbs within 2 years. The DESolve® scaffold permits a wide range of expansion with a consequently reduced risk for strut fracture. Lumen and scaffold enlargement is observed within 3–6 months in both preclinical and clinical studies potentially allowing for the scaffolded region to respond to vasoactive stimuli. The device has a unique property of self-correction observed in bench top studies, which in clinical practice has the potential to eliminate minor malapposition following deployment. Highlights: DESolve® has demonstrated preclinical and clinical safety and effectiveness. DESolve® has demonstrated a restoration of vasomotion after implantation. DESolve® possesses "self-correction" property. DESolve® Cx platform is the first scaffold to have a 120 μm strut thickness.